Halozyme Therapeutics (HALO) Balance Sheet

Click line-items for a historical chart and %

Cash and cash equivalents
Accounts receivable
Inventory
Prepaid expenses and other assets
Total current assets
Property and equipment, net
Total Assets
Accounts payable
Accrued expenses
Deferred revenue
Total current liabilities
Deferred revenue, net of current portion
Deferred rent, net of current portion
Commitments and contingencies (Note 11)
Preferred stock - $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 150,000,000 shares authorized; 103,609,419 and 100,580,849 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total Liabilities and Stockholders' Equity

Entities mentioned with HALO

View All Entities